Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_86555
Title of the Manuscript:	EFFICACY OF AND SAFETY OF SECUKINUMAB IN PSORIASIS VULGARIS; A PROSPECTIVE STUDY
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of 'lack of Novelty', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(https://www.journaljpri.com/index.php/JPRI/editorial-policy)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	The major issue of this study is the fact, that it is not new – the results are confirmatory. The data presentation should be modified – please include a graph. Were any concomitant therapy allowed, e.g. topic treatment? How many patients dropped during the study periods. Tables 1-3 can be merged into one table. It is really strange that in a group of more than 100 patients over 1 year no "side effects" were observed. Any common cold? Any headache? What about other adverse events?	
Minor REVISION comments	The authors have to clearly indicate the limitations of the study – e.g. open label design, no comparison arm, etc. The following statement has to be modified: This study concluded that Secukinumab has superior efficacy with excellent skin clearance Superior over what? Excellent is also confusing – why the authors state that? In fact there are 4 agents blocking IL-17 – bimekizumab is already approved is some countries.	
Optional/General comments	The introduction has to be shortened and focused on the most relevant aspects.	

PART 2:

		Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	

Reviewer Details:

Name:	Adam Reich
Department, University & Country	University of Rzeszow, Poland

Created by: EA Checked by: ME Approved by: CEO Version: 1.6 (10-04-2018)